# Safety and Immunogenicity of HPV Vaccine Administered Intradermally and Intramuscularly Via Needle-Free Injection System

> **NCT06142461** · PHASE2 · WITHDRAWN · sponsor: **PharmaJet, Inc.**

## Conditions studied

- Vaccine Reaction

## Interventions

- **DRUG:** Gardasil
- **DRUG:** Gardasil
- **DRUG:** Gardasil
- **DEVICE:** PharmaJet Stratis® Needle-Free Injection System
- **DEVICE:** PharmaJet Tropis® Needle-Free Injection System

## Key facts

- **NCT ID:** NCT06142461
- **Lead sponsor:** PharmaJet, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-05-31
- **Primary completion:** 2024-12-30
- **Final completion:** 2025-04-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Change in landscape of HPV treatment
- **Last updated:** 2024-05-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06142461

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06142461, "Safety and Immunogenicity of HPV Vaccine Administered Intradermally and Intramuscularly Via Needle-Free Injection System". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06142461. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*